|
News For MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA From The Last 14 Days Check below for free stories on MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA the last two weeks. |
|
|
| June 11, 2013 |
| 05:50 EDT |  | TEVA | U.S. to now comply with ruling on morning-after pill, WSJ reports
In a reversal, the U.S. government said it would allow emergency contraceptive Plan B to be sold in drugstores without restrictions and would end an appeal in a long-running court case, reports the Wall Street Journal. Reference Link |
|
| June 10, 2013 |
| 07:40 EDT |  | CELG, PFE | Leerink's biotech analyst holds analyst/industry conference call on ASCO
 Subscribe for More Information |
|
| 07:20 EDT | | PFE, TEVA | Biomed to host a conference
Subscribe for More Information |
|
| 05:25 EDT |  | AZN | AstraZeneca acquires Pearl Therapeutics for up to $1.15B
AstraZeneca announced that it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease. Under the terms of the agreement, AstraZeneca will acquire 100% of Pearl's shares for initial consideration of $560M payable on completion. In addition, deferred consideration of up to $450M becomes payable if specified development and regulatory milestones in respect of any triple combination therapies and selected future products that AstraZeneca develops using Pearl's technology platform are achieved. Sales-related payments of up to a further $140M are payable if pre-agreed cumulative sales thresholds are exceeded resulting in a total potential acquisition cost of up to $1.15B. The proposed transaction is subject to customary regulatory approvals and is expected to close in the Q3 of 2013. The acquisition of Pearl Therapeutics has no impact on AstraZeneca's financial guidance for 2013. |
|
| June 7, 2013 |
| 09:33 EDT | | CELG | Celgene management to meet with Lazard Capital
Meeting to be held in Zurich on June 14 hosted by Lazard Capital. |
|
| June 6, 2013 |
| 08:30 EDT | | TEVA | Federal appeals court orders access to contraceptive, WSJ reports
Subscribe for More Information |
|
| 07:33 EDT |  | TEVA | Teva Laquinimod could become $1B franchise, says Bernstein
Subscribe for More Information |
|
| 07:01 EDT | | AZN | Isis Pharmaceuticals earns $6M payment from AstraZeneca
Subscribe for More Information |
|
| 06:19 EDT |  | CELG | Celgene implied volatility at upper end of index mean range
|
|
|
|
|
|
